WHO Prequalification: Gateway to African Tenders

Why PQ Matters: The Gateway Effect

WHO PQ is not just a certificate—it's a key that unlocks multiple doors simultaneously.

1. Donor & UN Procurement (The Primary Market):

• Global Fund: PQ is mandatory for most products procured through Global Fund grants. The Global Fund disburses over $4 billion annually for HIV/AIDS, TB, and malaria programs.
• UNICEF: PQ required for vaccines and essential medicines in UNICEF supply catalog. UNICEF procures over $3 billion in health supplies annually.
• UNFPA: PQ required for reproductive health products.
• WHO: PQ products are preferred for WHO procurement and emergency stockpiles.
• World Bank, USAID, PEPFAR: While not mandatory, PQ products are strongly preferred.

2. African Regulatory Recognition (Fast-Track Registration):

Over 40 African countries have expedited registration pathways for WHO PQ products:

• Ethiopia (EFDA): 4-8 months for PQ vs. 12-18 months standard
• Kenya (PPB): 4-6 months for PQ vs. 8-12 months standard
• Tanzania (TMDA): 5-7 months for PQ vs. 10-14 months standard
• Uganda (NDA): 4-6 months for PQ vs. 8-12 months standard
• Nigeria (NAFDAC): 6-9 months for PQ vs. 12-18 months standard
• Zambia (ZAMRA): 4-7 months for PQ vs. 8-12 months standard
• Ghana (FDA): 4-6 months for PQ vs. 9-15 months standard

3. Government Tender Preference:

Many African governments give preference to WHO PQ products in national tenders:

• Higher quality scores (10-20% advantage)
• Reduced documentation requirements
• Waived local testing in some countries
• Priority evaluation in tender committees

4. Private Sector Credibility:

Even in private markets, WHO PQ is a powerful differentiator. Hospitals, pharmacy chains, and private insurers recognize PQ as a mark of quality, allowing premium pricing.

Eligible Products: What Can Be Prequalified?

WHO PQ is not available for all products. The program focuses on priority medicines for global health.

Priority Disease Areas:

• HIV/AIDS: Antiretrovirals (ARVs), opportunistic infection treatments
• Malaria: Artemisinin-based combination therapies (ACTs), diagnostics
• Tuberculosis (TB): First-line and second-line TB medicines
• Reproductive Health: Contraceptives, maternal health medicines
• Neglected Tropical Diseases (NTDs): Medicines for sleeping sickness, leishmaniasis, etc.
• Hepatitis: Hepatitis B and C treatments
• COVID-19: Vaccines, therapeutics, diagnostics
• Essential Medicines: Antibiotics, analgesics, and other WHO Essential Medicines List products

Product Types:

• Finished pharmaceutical products (tablets, capsules, injectables, syrups, etc.)
• Active Pharmaceutical Ingredients (APIs) for PQ products
• Vaccines (separate PQ pathway)
• Medical devices (condoms, diagnostics, etc.)

Products NOT Eligible:

• Products not on WHO priority list
• Biologics (except vaccines, insulin, and certain others)
• Medical devices not on priority list

Prerequisites: What You Need Before Applying

Before submitting to WHO PQ, ensure your product and facility meet these requirements.

Product Requirements:

• Product must be a generic version of a prequalified reference product (for most medicines)
• Bioequivalence study (for solid oral dosage forms) or clinical data (for other products)
• Stability data: 6 months accelerated, 12 months long-term at submission (Zone IV for tropical climates)
• Full CTD dossier (Modules 1-5) in English
• Patent declaration (product doesn't infringe patents in target countries)

Facility Requirements:

• Manufacturing site must comply with WHO GMP standards
• Quality Management System in place
• Site Master File (SMF) prepared
• Previous GMP inspection report (if available) from SRA or WHO PQ

Documentation Requirements:

• Certificate of Pharmaceutical Product (CPP) from home regulator
• GMP certificate from home regulator (if available)
• Product registration in country of origin (recommended but not mandatory)

Step-by-Step PQ Process

Here's the actual process for obtaining WHO Prequalification. It is rigorous and lengthy.

Step 0: Confirm Eligibility

Check the WHO PQ website for open Expressions of Interest (EOI) for your product category. Submit an EOI to confirm eligibility before investing in dossier preparation.

Step 1: Prepare Your CTD Dossier

Compile a complete CTD dossier (Modules 1-5) in English. This typically takes 6-12 months and requires significant resources. Most applicants use specialized regulatory consultants.

Step 2: Conduct Necessary Studies

Ensure you have:

• Bioequivalence study (for solid oral generics) from a WHO PQ-accepted center
• 12 months of long-term stability data (Zone IV)
• 6 months of accelerated stability data
• All batch records and analytical methods validated

Step 3: Submit Dossier to WHO PQ

Submit your dossier electronically via the WHO PQ portal. No fee for submission (unlike most regulators).

Step 4: Administrative Screening (2-3 months)

WHO PQ checks for completeness, format, and basic requirements. Incomplete submissions are rejected early to save time.

Step 5: Scientific Assessment (8-12 months)

WHO PQ evaluators (typically 2-3) review your dossier across:

• Pharmaceutical quality (Module 3)
• Bioequivalence/clinical data (Module 5)
• Labeling and product information

Queries are issued via the portal. You have 60-90 days to respond. Well-prepared dossiers have 2-3 query cycles. Poor dossiers may be rejected.

Step 6: GMP Inspection (Scheduled concurrently or after assessment)

Once the dossier passes initial assessment, WHO PQ schedules a GMP inspection of your manufacturing facility. See detailed inspection section below.

Step 7: Bioequivalence Study Verification (if applicable)

WHO PQ may verify your BE study with the contract research organization (CRO) that conducted it.

Step 8: Expert Committee Review (2-3 months)

After assessment and inspection are complete, the WHO PQ Expert Committee reviews the file for final approval.

Step 9: Prequalification Granted

Your product is added to the WHO PQ list. Certificate issued. Your product is now eligible for UN procurement.

Dossier Requirements: The WHO PQ Format

WHO PQ follows the CTD format (Modules 1-5), aligned with ICH guidelines.

Module 1: Administrative Information

• Application letter on manufacturer letterhead
• Product information summary
• Certificate of Pharmaceutical Product (WHO format, less than 2 years old)
• GMP certificate (if available)
• Manufacturing license
• Reference product information (for generics)
• Patent declaration
• Bioequivalence study summary (if applicable)

Module 2: Summaries

• Quality Overall Summary (QOS)
• Bioequivalence/Clinical Summary
• Nonclinical Summary (if applicable)

Module 3: Quality (Pharmaceutical Documentation)

• Drug substance (API): Manufacturing process, characterization, impurity profile, specifications, stability
• Drug product: Formulation, manufacturing process, specifications, excipients
• Stability data: Zone IV (hot and humid) - 6 months accelerated, 12 months long-term minimum at submission
• Container closure system: Packaging specifications
• Analytical methods validation

Module 4: Nonclinical Reports (for NCEs only)

Module 5: Clinical/Bioequivalence Reports

• Bioequivalence study report (for solid oral generics) from WHO PQ-accepted CRO
• Clinical study reports (for other product types)

GMP Inspection: The Site Visit

The GMP inspection is often the most challenging part of the PQ process. WHO PQ inspectors are among the most rigorous in the world.

What Triggers an Inspection?

• Every manufacturing site for a PQ product must be inspected
• Initial inspection for first-time applicants
• Re-inspection every 2-3 years to maintain PQ status
• For-cause inspections if issues arise

Inspection Process:

1. WHO PQ schedules inspection (8-12 weeks notice)
2. No fee for the inspection (WHO covers inspector costs, but your facility must cover local expenses)
3. 2-3 WHO inspectors visit for 4-5 days
4. They review:
   • Quality Management System
   • Production areas (cleanliness, segregation, validation)
   • Quality Control laboratory
   • Warehousing and storage
   • Water system and HVAC
   • Training records
   • Complaint handling and recall procedures
   • Data integrity (ALCOA+ principles)
5. They issue an inspection report with findings (critical, major, minor)
6. You submit a CAPA plan within 30 days
7. WHO may require re-inspection for critical findings

Common Inspection Findings:

• Inadequate data integrity controls
• Poor cleaning validation
• Insufficient environmental monitoring
• Incomplete batch records
• Unvalidated analytical methods
• Lack of quality risk management

Bioequivalence & Clinical Data Requirements

For generic solid oral dosage forms, a bioequivalence (BE) study is required.

BE Study Requirements:

• Must compare against a WHO PQ-listed reference product (or an SRA-approved reference)
• Must be conducted at a WHO PQ-accepted bioequivalence center
• Full study report with raw data must be submitted
• Study must follow WHO or EMA/FDA BE guidelines

WHO PQ-Accepted BE Centers:

• Centers that have been inspected and approved by WHO PQ
• List published on WHO PQ website
• Includes centers in India, South Africa, Kenya, Jordan, Europe, and North America

Waivers (Biowaivers):

• BCS Class I and III drugs may qualify for biowaiver
• Requires scientific justification and BCS classification data
• Not guaranteed—WHO PQ evaluates on a case-by-case basis

Costs, Timelines & Resource Planning

WHO PQ is a significant investment. Plan carefully.

Official WHO PQ Fees:

• Submission fee: $0 (WHO does not charge for PQ applications)
• Inspection fee: $0 (WHO covers inspector costs)
• Annual maintenance: $0

Note: While WHO charges no fees, your internal and consultant costs are substantial.

Your Costs (The Real Investment):

• Regulatory consultant fees: $50,000-150,000+
• Bioequivalence study: $50,000-150,000
• Stability studies (Zone IV): $20,000-50,000
• GMP readiness consulting: $30,000-100,000
• Facility upgrades (if needed): $50,000-500,000+
• Document preparation and translation: $10,000-30,000
• Internal staff time: Significant

Total Estimated Cost:

• Minimum (well-prepared facility, existing BE study): $80,000-150,000
• Typical (some gaps, new BE study): $150,000-300,000
• Maximum (significant facility upgrades needed): $300,000-1,000,000+

Timelines:

• Dossier preparation: 6-12 months
• BE study (if needed): 6-12 months
• Stability data collection: 12-18 months
• WHO PQ assessment: 8-12 months
• GMP inspection: 1-3 months (scheduling)
• Total: 18-30 months from decision to PQ

Benefits of PQ: Tender Access & Regulatory Recognition

Once you have WHO PQ, the doors open. Here's what you gain.

UN & Donor Tender Access:

• Global Fund: Submit PQ certificate to become a registered supplier. Access $4B+ annual procurement.
• UNICEF: List your product in UNICEF Supply Catalog. Access $3B+ annual procurement.
• UNFPA: Reproductive health products.
• WHO: Emergency stockpile procurement.
• World Bank, USAID, PEPFAR: PQ products are strongly preferred.

African Regulatory Fast-Track:

PQ products receive expedited registration in over 40 African countries:

• Ethiopia: 4-8 months (vs. 12-18 months standard)
• Kenya: 4-6 months (vs. 8-12 months)
• Nigeria: 6-9 months (vs. 12-18 months)
• Tanzania: 5-7 months (vs. 10-14 months)
• Uganda: 4-6 months (vs. 8-12 months)
• Zambia: 4-7 months (vs. 8-12 months)
• Ghana: 4-6 months (vs. 9-15 months)

Government Tender Preference:

• Higher quality scores (10-20% advantage)
• Reduced documentation requirements
• Waived local testing in some countries
• Priority evaluation

PQ in Africa: Regulatory Recognition Across the Continent

WHO PQ is recognized by African regulators at an unprecedented scale.

Countries with Formal PQ Fast-Track Pathways:

• East Africa: Kenya, Tanzania, Uganda, Rwanda, Burundi, South Sudan (via EAC harmonization)
• West Africa: Nigeria, Ghana, Côte d'Ivoire, Senegal, Mali (via ECOWAS harmonization)
• Southern Africa: Zambia, Zimbabwe, Botswana, Namibia (via ZaZiBoNa harmonization)
• North Africa: Morocco, Egypt, Tunisia (fast-track for PQ products)
• Central Africa: Cameroon, DRC (recognition increasing)

The EAC Advantage:

If you have WHO PQ, the EAC Joint Assessment Procedure (JAP) becomes even faster. PQ products are prioritized, and many EAC countries issue national registrations within 1-3 months of PQ.

The ZaZiBoNa Advantage:

Similarly, the SADC ZaZiBoNa collaborative registration process gives priority to WHO PQ products. You can be registered in Zambia, Zimbabwe, Botswana, and Namibia within 4-6 months with PQ.

Common Pitfalls & Rejection Reasons

• Incomplete Dossier: Missing Modules or critical data. WHO PQ rejects incomplete submissions early.
• Inadequate Stability Data: Zone II data instead of Zone IV. Insufficient time points.
• BE Study Not from WHO PQ-Accepted Center: Most common and expensive mistake.
• Poor Quality GMP Documentation: Incomplete Site Master File, missing validation reports.
• Data Integrity Issues: This is a major focus for WHO PQ inspectors.
• Reference Product Issues: Using a reference product that is not WHO PQ-listed or SRA-approved.
• Patent Infringement: Failing to declare patents or infringing on existing patents.
• Inadequate Response to Queries: Partial or poor-quality responses lead to rejection.

Post-PQ Obligations: Maintaining Your Status

WHO PQ is not a one-time achievement. You must maintain your status.

• Annual reporting: Submit annual updates to WHO PQ including any changes to manufacturing, specifications, or quality systems.
• Re-inspection: Your facility will be re-inspected every 2-3 years.
• Variations: Any change to manufacturing site, process, or specifications requires WHO PQ approval.
• Stability updates: Continue stability monitoring and report results annually.
• Pharmacovigilance: Maintain a PV system and report adverse events to WHO PQ.
• Product recall capability: Maintain a recall system and report any recalls.

PQ vs. SRA Approval: Which is Better for Africa?

Many manufacturers ask whether WHO PQ or SRA approval (US FDA, EMA) is better for African markets.

The Ideal Combination:

The most powerful combination is both WHO PQ and an SRA approval. This gives you:

• UN procurement access (from PQ)
• Fast-track in all PQ-recognizing countries
• Reference country recognition in non-PQ countries
• Credibility with private sector and governments

Conclusion: Your PQ Strategy

WHO Prequalification is the single most valuable regulatory asset for pharmaceutical exporters targeting Africa. It is expensive, demanding, and time-consuming—but it transforms your market access potential.

Your WHO PQ checklist:

• ✓ Confirm your product is eligible (check WHO PQ EOI)
• ✓ Ensure your facility meets WHO GMP standards (conduct gap assessment)
• ✓ Obtain Zone IV stability data (6 months accelerated, 12 months long-term minimum)
• ✓ Conduct BE study at WHO PQ-accepted center (if applicable)
• ✓ Hire experienced regulatory consultant with PQ track record
• ✓ Budget $150,000-300,000 and 18-24 months
• ✓ Prepare complete CTD dossier in English
• ✓ Submit to WHO PQ (no submission fee)
• ✓ Prepare for rigorous GMP inspection
• ✓ After PQ, fast-track African registrations (40+ countries)
• ✓ Register with Global Fund, UNICEF, and other UN agencies
• ✓ Bid on tenders across Africa with PQ advantage
• ✓ Maintain PQ status with annual reporting and re-inspections

Is WHO PQ worth it? For manufacturers of essential medicines targeting African markets, absolutely yes. The investment is substantial, but the return—access to billions in UN procurement, fast-track registration across the continent, and tender preference—is transformative.

Start with WHO PQ. It is the foundation of a successful African pharmaceutical export strategy. Once you have PQ, you have the key that unlocks the continent.